



Small but heading for the big time

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply

Paris, France, 15 April, 2014 – NANOBOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced the appointment of Thierry Otin as Head of Manufacturing and Supply. The appointment strengthens the Nanobiotix organisation, Mr Otin will be responsible for the manufacturing plans to move the lead product, NBTXR3, from clinical trials into full commercialization as from 2016.

Prior to joining Nanobiotix, he worked in QA/GMP and manufacturing with world class companies including, Schering CISBiointernational, Institut de Formation des Industries de Santé (IFIS), UCB, Delagrangé and Rhône-Poulenc (Roger Bellon and Specia). Mr Otin was also the Quality Site Manager (EU Sterile) at Roche and before then, he worked at LFB Biotechnologies as the Head Pharmacist (Pharmaceutical Qualified Person) and Quality Director. He has a degree in biology and has a doctorate in Pharmacy from the University of Strasbourg.

Laurent Levy, CEO of Nanobiotix said: *“Thierry Otin joins us having had over 30 years’ experience in the global pharmaceutical industry which includes 12+ years’ experience of injectable drug production management and 11+ years in QA senior compliance management. This wealth of expertise will be invaluable to us as we move our lead product to commercialization. We welcome him to the team.”*

-Ends-

About NANOBOTIX - www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

For more information, please contact:

Nanobiotix

Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
contact@nanobiotix.com

Financial communication and investors relations

NewCap
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53
lvdelouvrier@newcap.fr



Media relations

France - **NewCap**
Annie-Florence Loyer / Nadège Le Lezec
+33 (0)6 88 20 35 59
afloyer@newcap.fr / nlelezed@newcap.fr

Outside France - **Instinctif Partners** (formerly College Hill)
Melanie Toyne Sewell / Katherine Lynch / Donia Al Saffar
+44 (0) 207 457 2020
nanobiotix@instinctif.com